Rituximab combined with ABVD regimen in treatment of Hodgkin lymphoma with autoimmune hemolytic anemia: report of one case and review of literature
10.3760/cma.j.cn115356-20210505-00107
- VernacularTitle:利妥昔单抗联合ABVD方案治疗霍奇金淋巴瘤合并自身免疫性溶血性贫血一例并文献复习
- Author:
Yan YAN
1
;
Xiaofei CHAI
;
Jianwei DU
;
Xue GAO
;
Yufu LI
;
Yongping SONG
;
Quande LIN
Author Information
1. 河南省肿瘤医院血液科 郑州大学附属肿瘤医院 河南省血液病研究所，郑州 450008
- Keywords:
Lymphoma, Hodgkin;
Anemia, hemolytic, autoimmune;
Rituximab;
Antineoplastic combined chemotherapy protocols
- From:
Journal of Leukemia & Lymphoma
2021;30(12):735-738
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the efficacy of rituximab combined with ABVD (epirubicin+ bleomycin+ vindesine +dacarbazine) regimen in treatment of Hodgkin lymphoma (HL) complicated with autoimmune hemolytic anemia (AIHA).Methods:The clinical data of 1 HL patient complicated with AIHA in November 2019 in Henan Cancer Hospital were retrospectively analyzed, and literatures were reviewed.Results:The patient received left cervical lymph node biopsy and bone marrow biopsy, and then lymphoma-related gene mutations and whole genetic genome detection were performed. The patient was diagnosed as HL (tuberous sclerosis in stage Ⅳ) complicated with AIHA. After 6 cycles of rituximab combined with ABVD regimen, the efficacy was evaluated. This patient's anemia was recovered, and HL also achieved complete remission.Conclusions:Rituximab combined with ABVD regimen is effective in treatment of HL patients complicated with AIHA.
